Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enanta Pharmaceuticals

7.50
+0.09001.21%
Post-market: 7.500.00000.00%19:40 EDT
Volume:243.94K
Turnover:1.84M
Market Cap:160.32M
PE:-1.65
High:7.87
Open:7.21
Low:7.16
Close:7.41
Loading ...

Enanta Pharmaceuticals to Present Phase 2 Study Data on Zelicapavir at ESPID Annual Meeting

Reuters
·
22 May

Enanta Pharmaceuticals Announces Data From Its Phase 2 Study of Zelicapavir in Children With Respiratory Syncytial Virus to Be Presented at the 43Rd Annual Espid Meeting

THOMSON REUTERS
·
22 May

Evercore ISI Reaffirms Their Buy Rating on Enanta Pharmaceuticals (ENTA)

TIPRANKS
·
14 May

Enanta Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Enanta Pharma Q2 EPS $(1.06) Beats $(1.14) Estimate, Sales $14.93M Miss $15.95M Estimate

Benzinga
·
13 May

Enanta reports Q2 EPS ($1.06), consensus ($1.14)

TIPRANKS
·
13 May

Enanta Pharmaceuticals Reports Decrease in Revenue to $14.9 Million in Q2 2025 from $17.1 Million in Q2 2024

Reuters
·
13 May

BRIEF-Enanta Pharmaceuticals Q2 Revenue USD 14.926 Million

Reuters
·
13 May

Enanta Pharmaceuticals Inc - Expects Cash Sufficiency Into Fiscal 2028

THOMSON REUTERS
·
13 May

Enanta Pharmaceuticals Q2 Revenue USD 14.926 Million

THOMSON REUTERS
·
13 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
12 May

Enanta Pharmaceuticals Inc expected to post a loss of $1.14 a share - Earnings Preview

Reuters
·
09 May

Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts

Insider Monkey
·
06 May

Top Premarket Gainers

MT Newswires Live
·
05 May

Enanta Pharmaceuticals Inc expected to post a loss of $1.14 a share - Earnings Preview

Reuters
·
02 May

BRIEF-Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation At Escmid Global 2025

Reuters
·
08 Apr

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Business Wire
·
08 Apr

Top Premarket Gainers

MT Newswires Live
·
24 Mar

Enanta Pharmaceuticals Stockholders Approve Key Proposals in 2025

TIPRANKS
·
18 Mar

Enanta Pharmaceuticals: Hold Rating Amid Delayed Launches and Strategic Advancements

TIPRANKS
·
25 Feb